MedTrace Logo

SFX-01 After Subarachnoid Haemorrhage

NCT02614742 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-01-18

No results posted yet for this study

Summary

This is a Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SFX-01 in Subarachnoid Haemorrhage, with exploratory evaluations of efficacy.

Conditions

  • Subarachnoid Hemorrhage, Spontaneous

Interventions

DRUG

SFX-01

An intervention releasing sulforaphane.

DRUG

Placebo

Placebo otherwise identical to Active product

Sponsors & Collaborators

  • Evgen Pharma

    lead INDUSTRY

Principal Investigators

  • Diederik Bulters, MBChB, BSc · University Hospital Southampton NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-09-30
Completion
2019-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614742 on ClinicalTrials.gov